The fiscal year 2025 closed with a dramatic reshuffling at the pinnacle of the pharmaceutical industry’s sales leaderboard, signaling profound shifts driven by therapeutic innovation and evolving global health priorities. While Merck’s oncology blockbuster, Keytruda (pembrolizumab), staunchly maintained its position as the top-selling individual brand, a monumental competitive surge from the GLP-1 agonist class saw Eli Lilly’s tirzepatide (Mounjaro, Zepbound) and Novo Nordisk’s semaglutide (Ozempic, Wegovy) collectively surpass Keytruda at the molecular level. This distinction underscores a critical nuance in market analysis, highlighting the diversified applications and rapid adoption of these metabolic powerhouses across diabetes and obesity indications. Beyond this high-stakes contest, the FY2025 data paints a picture of robust growth within scaled specialty franchises, particularly in immunologicals, which defied a broader trend of pipeline contraction to post impressive gains.
The Ascendancy of GLP-1 Agonists: A Paradigm Shift
The story of FY2025 is inextricably linked to the meteoric rise of GLP-1 receptor agonists, a class of drugs originally developed for Type 2 diabetes that has since revolutionized weight management. Eli Lilly’s Mounjaro, an innovative dual GIP/GLP-1 receptor agonist, emerged as a formidable challenger, recording an astonishing 99.0% year-over-year growth to reach $22.97 billion in sales. Its sibling drug, Zepbound, approved specifically for chronic weight management, posted an even more staggering 174.9% growth, climbing to $13.54 billion. Combined, tirzepatide’s molecular sales unequivocally outstripped Keytruda’s brand revenue.
Novo Nordisk, the pioneer in the GLP-1 space, continued its strong performance with Ozempic (semaglutide for Type 2 diabetes) achieving $19.21 billion and Wegovy (semaglutide for weight management) soaring to $11.96 billion, marking a 35.9% increase. The combined might of semaglutide, much like tirzepatide, cemented its molecular dominance. This unprecedented growth reflects not only the high efficacy of these compounds but also the vast, previously underserved patient populations grappling with Type 2 diabetes and obesity globally. The World Health Organization estimates that over 1 billion people worldwide are obese, with projections indicating a continued rise, establishing a significant market for effective interventions.
The journey of GLP-1 agonists to blockbuster status began with their initial approvals for Type 2 diabetes, leveraging their ability to enhance insulin secretion, suppress glucagon, and slow gastric emptying. However, the profound weight loss observed in clinical trials quickly propelled them into the obesity treatment landscape. Regulatory approvals for weight management, such as the FDA’s nod for Wegovy in 2021 and Zepbound in 2023, catalyzed an explosion in demand. This chronological expansion of indications underscores a strategic evolution from diabetes management to a broader metabolic health platform, with implications for cardiovascular outcomes and other obesity-related comorbidities now being extensively explored.
Executives from both Eli Lilly and Novo Nordisk have frequently expressed profound optimism regarding the long-term potential of these therapies. Inferred statements from leadership would likely emphasize their commitment to expanding access, driving further research into additional indications (e.g., heart failure with preserved ejection fraction, sleep apnea), and scaling manufacturing to meet escalating demand. Simultaneously, healthcare providers and payers are navigating the complex landscape of ensuring equitable access while managing the substantial costs associated with these highly effective, yet premium-priced, treatments. Discussions around insurance coverage, patient assistance programs, and the societal value of addressing chronic diseases like obesity are central to the ongoing discourse.
Keytruda’s Sustained Dominance in Oncology
Despite the GLP-1 surge, Merck’s Keytruda demonstrated remarkable resilience and continued growth, solidifying its position as the pharmaceutical industry’s leading individual brand. With FY2025 sales reaching $31.68 billion, a robust 7.5% increase from the previous year, Keytruda’s performance underscores the enduring and expanding role of immunotherapy in cancer treatment. As a programmed death receptor-1 (PD-1) blocking antibody, Keytruda works by unleashing the body’s immune system to fight various cancers. Its success is rooted in its broad applicability, having secured approvals across a multitude of cancer types, including melanoma, lung cancer, head and neck cancer, classical Hodgkin lymphoma, and many others, often serving as a first-line treatment.
The distinction between Keytruda’s brand leadership and the molecular supremacy of tirzepatide and semaglutide is critical. Keytruda represents a single therapeutic entity marketed under one brand name for diverse oncological indications. In contrast, tirzepatide and semaglutide, while single molecules, are marketed under multiple brand names (Mounjaro/Zepbound and Ozempic/Wegovy, respectively) to target different patient populations and indications (diabetes vs. obesity). This highlights Keytruda’s singular market penetration and the consistent demand for its life-extending benefits across a broad spectrum of oncological care.
Merck executives, in their financial reports and investor calls, would undoubtedly highlight Keytruda’s continued impact on patient survival and quality of life, attributing its sustained growth to expanding indications, earlier treatment lines, and global market penetration. The drug’s robust clinical development program, which continually seeks new applications and combinations, ensures its relevance in a rapidly evolving oncology landscape. However, the future for Keytruda, like all biologics, will eventually involve navigating the challenges of patent expiration, anticipated in the early 2030s, which will introduce biosimilar competition and potentially reshape the oncology market. For now, its reign remains undisputed in the brand category, a testament to its profound clinical value.
The Robust Expansion of Specialty Franchises, Led by Immunologicals
Beyond the top-tier battles, the FY2025 data revealed a strong and consistent upward trajectory for several scaled specialty franchises, demonstrating their capacity for sustained compounding growth rather than market saturation. This trend was particularly pronounced within the immunological therapeutic area, which recorded an impressive 20.6% expansion, even as the overall pharmaceutical pipeline experienced a contraction. This robust growth in immunologicals contrasts sharply with the broader industry’s challenges, signaling a strategic shift towards high-value, targeted therapies for chronic and complex diseases.
Leading this charge were drugs like Sanofi/Regeneron’s Dupixent (dupilumab), which saw a 20.2% increase to $17.74 billion, cementing its role in treating atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. AbbVie’s Skyrizi (risankizumab), targeting psoriasis and psoriatic arthritis, demonstrated explosive growth of 49.9% to reach $17.56 billion. Similarly, AbbVie’s Rinvoq (upadacitinib) achieved a remarkable 39.1% growth, hitting $8.30 billion, showcasing its efficacy across rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Johnson & Johnson’s Darzalex (daratumumab) for multiple myeloma grew by 23.0% to $14.35 billion, and Tremfya (guselkumab) for psoriasis and psoriatic arthritis surged by 40.5% to $5.16 billion. Novartis’ Kisqali (ribociclib), an oncology drug for breast cancer, also posted significant growth of 57.7% to $4.78 billion.
These drugs represent the pinnacle of modern pharmaceutical innovation, addressing significant unmet medical needs in chronic autoimmune and inflammatory conditions, as well as specific cancers. Their success is driven by several factors:
- High Efficacy and Specificity: These biologics and targeted small molecules offer superior efficacy and more favorable safety profiles compared to older, broader-acting treatments.
- Expanding Indications: Many of these drugs continuously gain approvals for additional indications within their therapeutic areas, broadening their patient reach.
- Global Market Penetration: As healthcare systems worldwide improve access to advanced therapies, the global market for these specialty drugs expands.
- Patient Retention: For chronic conditions, patients often remain on these effective therapies for extended periods, contributing to sustained revenue streams.
The growth in immunologicals, in particular, highlights the pharmaceutical industry’s successful pivot towards precision medicine. These therapies often target specific cytokines or signaling pathways implicated in disease pathogenesis, leading to more tailored and effective treatments. This trend suggests that despite the high cost associated with developing and bringing these drugs to market, their clinical value and impact on patient lives justify the investment, reinforcing the focus on complex disease areas with significant unmet needs.
Shifting Tides: Declining Blockbusters and Emerging Innovators
While the narrative of FY2025 was largely dominated by growth, the sales data also revealed significant declines for several once-dominant blockbusters, underscoring the relentless cycle of innovation, patent expiration, and market competition. Notably, Johnson & Johnson’s Stelara (ustekinumab) experienced a substantial 41.3% drop in sales to $6.08 billion, primarily due to biosimilar competition following its patent expiration. Similarly, AbbVie’s long-standing autoimmune giant, Humira (adalimumab), continued its decline, plummeting by 49.5% to $4.54 billion, as a wave of biosimilars eroded its market share. Bristol Myers Squibb’s Revlimid (lenalidomide), a multiple myeloma drug, also saw a sharp 48.9% decrease to $2.95 billion, facing generic competition. These declines serve as a stark reminder of the "patent cliff" phenomenon that pharmaceutical companies must continually navigate.
The COVID-19 pandemic-era blockbusters also saw significant pullbacks. Pfizer/BioNTech’s Comirnaty vaccine sales decreased by 18.4% to $4.37 billion, and Pfizer’s antiviral Paxlovid plummeted by 58.7% to $2.36 billion, reflecting the global shift from acute pandemic response to endemic management and reduced demand for emergency treatments. Merck’s Gardasil, a HPV vaccine, also experienced a significant 39.0% decline to $5.23 billion, likely due to market dynamics and vaccination campaign fluctuations.
However, amidst these declines, the FY2025 data also highlighted the emergence of new contenders rapidly gaining traction. These newer drugs, while not yet at the very top of the sales charts, represent future growth drivers for their respective companies. Examples include:
- Reblozyl (BMS): A treatment for anemia in beta-thalassemia and myelodysplastic syndromes, grew by 31.2% to $2.33 billion.
- Cabenuva (GSK/ViiV): A long-acting injectable HIV regimen, surged by 38.4% to $1.85 billion.
- Breyanzi (BMS): A CAR T-cell therapy for lymphoma, saw remarkable 81.8% growth to $1.36 billion.
- Opdualag (BMS): A fixed-dose combination immunotherapy for melanoma, increased by 27.7% to $1.19 billion.
- Camzyos (BMS): For obstructive hypertrophic cardiomyopathy, expanded by 77.4% to $1.07 billion.
- Apretude (GSK/ViiV): A long-acting injectable for HIV pre-exposure prophylaxis (PrEP), grew by 57.1% to $578 million.
These emerging therapies underscore the ongoing innovation across diverse therapeutic areas, from rare blood disorders and HIV prevention to advanced cancer treatments and cardiovascular diseases. Their rapid growth trajectories indicate successful market entry, high clinical utility, and the potential to become future blockbusters as they gain broader adoption and potentially expand their indications.
Broader Industry Trends and Future Outlook
The FY2025 Pharma 50 report provides a crucial snapshot of an industry in flux, characterized by dynamic shifts in therapeutic focus, intense competition, and the relentless pursuit of innovation. The overall contraction of the pharmaceutical pipeline, as noted in the original analysis, suggests a more concentrated R&D effort, likely driven by escalating development costs, stringent regulatory requirements, and a strategic emphasis on high-potential assets. This concentration is evident in the continued dominance of oncology, the explosive growth in metabolic diseases, and the sustained expansion of immunologicals.
The financial performance of pharmaceutical companies in FY2025 reflects these trends. Companies with strong positions in GLP-1 agonists, such as Eli Lilly and Novo Nordisk, are experiencing significant revenue boosts, impacting their market valuations and investment strategies. Merck continues to benefit from Keytruda’s robust sales, while companies like AbbVie, Sanofi, and J&J are capitalizing on their growing specialty franchises. The industry’s strategic direction appears to be firmly anchored in developing highly targeted therapies that address significant unmet medical needs, command premium pricing, and offer substantial long-term growth potential.
Looking ahead, several key implications emerge from the FY2025 data:
- Continued GLP-1 Expansion: The market for GLP-1 agonists is far from saturated. Expect further research into new indications, oral formulations, and combination therapies, as well as a burgeoning pipeline of next-generation obesity and diabetes treatments.
- Oncology Innovation: While Keytruda dominates, the oncology landscape remains fiercely competitive, with ongoing advancements in cell therapies, gene therapies, and targeted small molecules driving future growth.
- Immunological Breakthroughs: The success of drugs like Dupixent and Skyrizi suggests a fertile ground for further innovation in autoimmune and inflammatory diseases, with a focus on more precise and personalized treatments.
- Navigating the Patent Cliff: Pharmaceutical companies must continually innovate to offset revenue losses from patent expirations, making strategic M&A and robust R&D pipelines critical for sustained growth.
- Access and Affordability: The high cost of many blockbuster specialty drugs will continue to fuel debates around drug pricing, insurance coverage, and global access, influencing policy decisions and healthcare system sustainability.
The data, meticulously compiled from primary company filings and standardized using precise currency conversion rates (e.g., DKK 6.617 for Novo Nordisk, EUR 0.886 for Sanofi/Regeneron, CHF 0.831 for Roche, GBP 0.759 for GSK), provides an authoritative overview of the industry’s financial health and strategic direction. FY2025 was a year that vividly demonstrated the pharmaceutical sector’s capacity for groundbreaking innovation and its dynamic response to global health challenges, while simultaneously highlighting the persistent commercial pressures and opportunities that define this critical industry.
Leave a Reply